"Radioimmunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
| Descriptor ID |
D016499
|
| MeSH Number(s) |
E02.095.465.425.750 E02.186.750 E02.815.520
|
| Concept/Terms |
Radioimmunotherapy- Radioimmunotherapy
- Radioimmunotherapies
- Immunoradiotherapy
- Immunoradiotherapies
|
Below are MeSH descriptors whose meaning is more general than "Radioimmunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Radioimmunotherapy".
This graph shows the total number of publications written about "Radioimmunotherapy" by people in this website by year, and whether "Radioimmunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 3 | 5 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radioimmunotherapy" by people in Profiles.
-
Multimodality treatment for recurrent neuroblastoma in the central nervous system. Pediatr Blood Cancer. 2023 04; 70(4):e30227.
-
FZD10-targeted a-radioimmunotherapy with 225 Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model. Cancer Sci. 2022 Feb; 113(2):721-732.
-
Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 10 01; 27(19):5188-5194.
-
Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci. 2021 Sep 03; 22(17).
-
Immunoradiotherapy goes club(bing). Nat Cancer. 2021 09; 2(9):871-872.
-
Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunol Immunother. 2021 Aug; 70(8):2411-2414.
-
Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite". Clin Cancer Res. 2020 06 15; 26(12):2777-2782.
-
a-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer Sci. 2018 Jul; 109(7):2302-2309.
-
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 08; 18(1):646.
-
In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy. Cancer Immunol Immunother. 2012 Aug; 61(8):1211-20.